Zal Bilimoria
Founding Partner @ Refactor
Burlingame, United States
Zal Bilimoria is a seed investor at Refactor in Burlingame focused on Biotechnology and Health Care. Zal is the solo partner at Refactor, a seed-stage firm focused on bio, climate, and hard tech investments. Previously, he helped launch the Bio Fund at a16z and prior to that, spent 10 years in product at Google, Netflix, and LinkedIn. He is an alumnus of the University of Pennsylvania.
- Total investments:
- 30
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Zal Bilimoria invests in
Stages Zal Bilimoria invests in
Countries Zal Bilimoria invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 8 (27%)
- Health Care 7 (23%)
- Medical 4 (13%)
- Internet 3 (10%)
- Therapeutics 3 (10%)
Stage
- Seed 14 (47%)
- Series A 4 (13%)
- Series B 3 (10%)
- Series C 3 (10%)
- Pre-Seed 1 (3%)
Country
- United States 15 (50%)
- New Zealand 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Causal Labs
|
Causal Labs provides AI physics models to predict and control the weather. | $6M / Seed / Mar 12, 2025 | |
MIIST Therapeutics
|
MIIST Therapeutics is a pulmonary drug delivery system and digital platform that enhances the science of inhaled drugs. In order to reduce the excessive quantity of death and sickness brought on by tobacco use, MIIST is actively developing technology that will be used as a smoking cessation therapy. | $7M / Seed / Feb 05, 2025 | |
General Galactic
|
General Galactic revolutionize the energy supply chain by producing synthetic hydrocarbons from air and waste CO2 using renewable electricity, making clean fuel affordable and accessible. General Galactic is developing technology to enable democratization of access to critical fuels at the site of need through modular hardware. | $8M / Seed / Oct 11, 2024 | |
Hexium
|
Hexium is advancing domestic isotope enrichment to initially power next-generation fission and fusion reactors. Building on proven AVLIS technology from Lawrence Livermore National Laboratory, Hexium’s team of global leaders in laser isotope separation and industrial-scale production are creating a reliable, scalable supply of isotopes, startingwith lithium-6 and lithium-7. Hexium is driving the transition to cleaner, safer, and more sustainable energy solutions. | $8M / Seed / Jul 24, 2024 | |
Rubedo Life Sciences
|
Rubedo Life Sciences mission is to treat age-related diseases to extend health-span targeting senescence and stem cells. | $40M / Series A / Apr 22, 2024 | |
Parallel Bio
|
Parallel Bio develops tools that help in the discovery and development of immunotherapies, to eliminate current barriers and create the fastest path to a drug that works. Parallel Bio's platform combines best-in-class human immune organoids with computational methods to generate unprecedented insights into human health and disease. | $4.3M / Seed / Dec 20, 2022 | |
Solugen
|
Solugen's mission is to decarbonize the chemicals industry. Solugen combines synthetic biology with metal catalysis to make carbon negative chemicals at scale.Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with thecompetition. | $350M / Series C / Sep 09, 2021 | |
|
Solugen
|
Solugen's mission is to decarbonize the chemicals industry. Solugen combines synthetic biology with metal catalysis to make carbon negative chemicals at scale.Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with thecompetition. | $357M / Series C / Sep 09, 2021 | |
Knowde
|
knowde is the online marketing platform dedicated to chemicals and ingredients. They make it easy to connect with customers, online. Use knowde Pages to get your products noticed every time a customer searches on any search engine. Build your knowde Page in an hour and get started for free. | $72M / Series B / Aug 05, 2021 | |
Astranis
|
Astranis develops small communications satellites designed for geostationary and other high Earth orbits. The company manufactures software-defined satellites used for broadband connectivity, government communications, navigation resilience, and space-based infrastructure applications. Its MicroGEO platform is built to provide dedicated satellitecapacity for telecommunications providers, enterprises, and public sector organizations serving remote or underserved regions. Astranis also develops satellite systems with onboard propulsion, radiation-hardened electronics, and configurable bandwidth management technologies for mission flexibility. The company operates across spacecraft design, satellite manufacturing, launch coordination, and in-orbit operations through integrated engineering and testing capabilities. Its satellite network solutions support internet connectivity, defense communications, and resilient positioning and navigation services for commercial and government customers. | $250M / Series C / Apr 14, 2021 | |
| See all 30 investments → | |||
Co-Investors
About Refactor
Refactor is a seed-stage VC firm investing in bio, climate, and hard tech startups run by Zal Bilimoria. Zal was a partner at a16z and PM for a decade at Google, Netflix, and LinkedIn. He led the seed rounds of Solugen, Astranis, and many other hard tech startups. He is the only decision maker at the firm, writing $1-2M checks in pre-seed and seedrounds.
Refactor Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Zal Bilimoria
Founding Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Zal Bilimoria invest in?
Zal Bilimoria invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Zal Bilimoria?
Public channels for Zal Bilimoria include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Zal Bilimoria last invest?
The most recent investment recorded for Zal Bilimoria closed in Mar 2025. Shizune tracks 30 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
